Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von HC Wainwright 

Iovance Biotherapeutics Inc. diskutieren

Iovance Biotherapeutics Inc.

WKN: A2DT49 / Symbol: IOVA / Name: Iovance Biotherapeutics / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /

8,52 €
-3,13 %

Einschätzung Buy
Rendite (%) 127,70 %
Kursziel 35,60
Veränderung
Endet am 01.03.24

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Ratings data for IOVA provided by MarketBeat

Einschätzung Buy
Rendite (%) 127,70 %
Kursziel 27,17
Veränderung
Endet am 01.03.24

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $29.00 price target on the stock.
Ratings data for IOVA provided by MarketBeat

Einschätzung Buy
Rendite (%) 4,72 %
Kursziel 15,85
Veränderung
Endet am 30.05.24

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $17.00 price target on the stock, up previously from $11.00.
Ratings data for IOVA provided by MarketBeat

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for IOVA provided by MarketBeat

Einschätzung Buy
Rendite (%) 33,26 %
Kursziel 26,26
Veränderung
Endet am 10.08.24

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $29.00 price target on the stock.
Ratings data for IOVA provided by MarketBeat

Einschätzung Buy
Rendite (%) 33,26 %
Kursziel 34,45
Veränderung
Endet am 10.08.24

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Ratings data for IOVA provided by MarketBeat

Einschätzung Buy
Rendite (%) 30,58 %
Kursziel 26,61
Veränderung
Endet am 16.08.24

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $29.00 price target on the stock.
Ratings data for IOVA provided by MarketBeat

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) was upgraded by analysts at StockNews.com to a "sell" rating.
Ratings data for IOVA provided by MarketBeat

Einschätzung Buy
Rendite (%) 67,47 %
Kursziel 15,92
Veränderung
Endet am 15.09.24

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $17.00 price target on the stock.
Ratings data for IOVA provided by MarketBeat

Einschätzung Buy
Rendite (%) 67,47 %
Kursziel 35,59
Veränderung
Endet am 15.09.24

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Ratings data for IOVA provided by MarketBeat

Einschätzung Buy
Rendite (%) 67,47 %
Kursziel 28,10
Veränderung
Endet am 15.09.24

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $30.00 price target on the stock.
Ratings data for IOVA provided by MarketBeat

Einschätzung Buy
Rendite (%) 95,95 %
Kursziel 26,24
Veränderung
Endet am 08.11.24

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target lowered by analysts at HC Wainwright from $38.00 to $28.00. They now have a "buy" rating on the stock.
Ratings data for IOVA provided by MarketBeat

Einschätzung Buy
Rendite (%) 68,79 %
Kursziel 10,98
Veränderung
Endet am 20.11.24

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $12.00 price target on the stock.
Ratings data for IOVA provided by MarketBeat

Einschätzung Buy
Rendite (%) 37,57 %
Kursziel 15,35
Veränderung
Endet am 27.12.24

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $17.00 price target on the stock.
Ratings data for IOVA provided by MarketBeat

Einschätzung Buy
Rendite (%) 32,73 %
Kursziel 25,20
Veränderung
Endet am 27.12.24

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target lowered by analysts at HC Wainwright from $38.00 to $28.00. They now have a "buy" rating on the stock.
Ratings data for IOVA provided by MarketBeat

Einschätzung Buy
Rendite (%) -19,43 %
Kursziel 31,41
Veränderung
Endet am 20.02.25

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target raised by analysts at Chardan Capital from $29.00 to $34.00. They now have a "buy" rating on the stock.
Ratings data for IOVA provided by MarketBeat

Einschätzung Buy
Rendite (%) -27,76 %
Kursziel 16,63
Veränderung
Endet am 20.02.25

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target raised by analysts at Piper Sandler from $14.00 to $18.00. They now have an "overweight" rating on the stock.
Ratings data for IOVA provided by MarketBeat

Einschätzung Buy
Rendite (%) -27,76 %
Kursziel 17,55
Veränderung
Endet am 20.02.25

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $13.00 to $19.00. They now have a "buy" rating on the stock.
Ratings data for IOVA provided by MarketBeat

Einschätzung Buy
Rendite (%) -27,15 %
Kursziel 20,35
Veränderung
Endet am 20.02.25

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target raised by analysts at Wells Fargo & Company from $17.00 to $22.00. They now have an "overweight" rating on the stock.
Ratings data for IOVA provided by MarketBeat

Einschätzung Buy
Rendite (%) -43,34 %
Kursziel 20,28
Veränderung
Endet am 28.02.25

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target raised by analysts at Barclays PLC from $18.00 to $22.00. They now have an "overweight" rating on the stock.
Ratings data for IOVA provided by MarketBeat